Targeting PKM2 presents a novel approach for cancer therapy. Inhibitors of PKM2's dimeric form could potentially shift the balance toward the more active tetrameric form, thereby disrupting the metabolic flexibility of cancer cells and inhibiting their growth. Additionally, therapies that exploit PKM2’s non-metabolic functions, such as its role in gene regulation, could also be explored. However, the challenge lies in selectively targeting cancer cells without affecting normal cells that also express PKM2.
